Hadasit Bio (HDST) - Total Assets
Based on the latest financial reports, Hadasit Bio (HDST) holds total assets worth ILA14.67 Million ILA (≈ $39.33K USD) as of June 2023. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See HDST book value for net asset value and shareholders' equity analysis.
Hadasit Bio - Total Assets Trend (2008–2022)
This chart illustrates how Hadasit Bio's total assets have evolved over time, based on quarterly financial data.
Hadasit Bio - Asset Composition Analysis
Current Asset Composition (December 2022)
Hadasit Bio's total assets of ILA14.67 Million consist of 41.2% current assets and 58.8% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 2.1% |
| Accounts Receivable | ILA0.00 | 0.0% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2008–2022)
This chart illustrates how Hadasit Bio's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HDST stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hadasit Bio's current assets represent 41.2% of total assets in 2022, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2022, down from 34.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Hadasit Bio Competitors by Total Assets
Key competitors of Hadasit Bio based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Peptron Inc
KQ:087010
|
Korea | ₩183.74 Billion |
|
Pluristem
TA:PSTI
|
Israel | ILA79.13 Million |
|
Purple Biotech Ltd
TA:KTOV
|
Israel | ILA85.78 Million |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
|
Panagene Inc
KQ:046210
|
Korea | ₩101.91 Billion |
Hadasit Bio - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.93 | 17.73 | 16.89 |
| Quick Ratio | 4.93 | 17.73 | 16.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA8.58 Million | ILA18.33 Million | ILA43.51 Million |
Hadasit Bio - Advanced Valuation Insights
This section examines the relationship between Hadasit Bio's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.52 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -41.3% |
| Total Assets | ILA38.95 Million |
| Market Capitalization | $2.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hadasit Bio's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hadasit Bio's assets decreased by 41.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hadasit Bio (2008–2022)
The table below shows the annual total assets of Hadasit Bio from 2008 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | ILA38.95 Million ≈ $104.43K |
-41.35% |
| 2021-12-31 | ILA66.41 Million ≈ $178.05K |
+60.50% |
| 2020-12-31 | ILA41.38 Million ≈ $110.94K |
+339.65% |
| 2019-12-31 | ILA9.41 Million ≈ $25.23K |
-73.36% |
| 2018-12-31 | ILA35.34 Million ≈ $94.73K |
-48.49% |
| 2017-12-31 | ILA68.60 Million ≈ $183.91K |
-1.23% |
| 2016-12-31 | ILA69.46 Million ≈ $186.21K |
+1.23% |
| 2015-12-31 | ILA68.61 Million ≈ $183.94K |
+111.64% |
| 2014-12-31 | ILA32.42 Million ≈ $86.91K |
-6.73% |
| 2013-12-31 | ILA34.76 Million ≈ $93.18K |
-19.52% |
| 2012-12-31 | ILA43.19 Million ≈ $115.78K |
-0.94% |
| 2011-12-31 | ILA43.60 Million ≈ $116.88K |
-28.59% |
| 2010-12-31 | ILA61.05 Million ≈ $163.66K |
+9.03% |
| 2009-12-31 | ILA55.99 Million ≈ $150.11K |
+165.29% |
| 2008-12-31 | ILA21.11 Million ≈ $56.58K |
-- |
About Hadasit Bio
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings L… Read more